0 XP   0   0   0

LUPIN LTD.
Buy, Hold or Sell?

Should you buy, hold or sell Lupin?

I guess you are interested in LUPIN LTD.. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

Let's analyse Lupin

Let's start. I'm going to help you getting a better view of LUPIN LTD.. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

  1. Company's Financial Health
    A deep dive into the books. How are the numbers doing? Is LUPIN LTD. even making a profit? Is the company skyrocketing? Or is it sinking like the Titanic. The trend is your friend.
  2. Market Valuation
    Finally, you now have an insight of how LUPIN LTD. is doing in the market. If the company is worth buying. The latest step is to find out how other investors value LUPIN LTD.. The closing price on 2023-01-27 was INR742.20 per share. Is the company over- or underpriced?
  3. Key Performance Indicators
    A total overlook on how the company is doing. Based on the (trends in) the key performance indicators.
LUPIN LTD. Daily Candlestick Chart
LUPIN LTD. Daily Candlestick Chart
Summary









1. Valuation of Lupin




Current price per share

INR742.20

2. Growth of Lupin




Is Lupin growing?

Current yearPrevious yearGrowGrow %
How rich?$1.4b$1.6b-$202.9m-13.6%

How much money is Lupin making?

Current yearPrevious yearGrowGrow %
Making money-$187.9m$149.6m-$337.5m-179.6%
Net Profit Margin-9.3%8.0%--

How much money comes from the company's main activities?

3. Financial Health of Lupin




Comparing to competitors in the Pharmaceuticals industry




  Industry Rankings (Pharmaceuticals)  


Richest
#5 / 54

Most Profit
#54 / 54


Summary

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

1.1. Profitability of LUPIN LTD..

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Lupin earns for each ₹1 of revenue.

  • Above 10% is considered healthy but always compare Lupin to the Pharmaceuticals industry mean.
  • A Net Profit Margin of -9.3% means that ₹-0.09 for each ₹1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of LUPIN LTD.:

  • The MRQ is -9.3%. The company is making a loss. -1
  • The TTM is -9.3%. The company is making a loss. -1
Trends
Current periodCompared to+/- 
MRQ-9.3%TTM-9.3%0.0%
TTM-9.3%YOY8.0%-17.3%
TTM-9.3%5Y0.5%-9.9%
5Y0.5%10Y7.6%-7.0%
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
MRQ-9.3%3.3%-12.6%
TTM-9.3%6.9%-16.2%
YOY8.0%9.9%-1.9%
5Y0.5%6.3%-5.8%
10Y7.6%6.7%+0.9%
1.1.2. Return on Assets

Shows how efficient Lupin is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Lupin to the Pharmaceuticals industry mean.
  • -7.0% Return on Assets means that Lupin generated ₹-0.07 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of LUPIN LTD.:

  • The MRQ is -7.0%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -7.0%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-7.0%TTM-7.0%0.0%
TTM-7.0%YOY5.2%-12.2%
TTM-7.0%5Y0.0%-7.0%
5Y0.0%10Y6.2%-6.2%
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
MRQ-7.0%0.8%-7.8%
TTM-7.0%1.3%-8.3%
YOY5.2%1.5%+3.7%
5Y0.0%1.4%-1.4%
10Y6.2%1.4%+4.8%
1.1.3. Return on Equity

Shows how efficient Lupin is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Lupin to the Pharmaceuticals industry mean.
  • -12.6% Return on Equity means Lupin generated ₹-0.13 for each ₹1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of LUPIN LTD.:

  • The MRQ is -12.6%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -12.6%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-12.6%TTM-12.6%0.0%
TTM-12.6%YOY8.8%-21.4%
TTM-12.6%5Y0.1%-12.6%
5Y0.1%10Y10.3%-10.3%
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
MRQ-12.6%1.5%-14.1%
TTM-12.6%2.0%-14.6%
YOY8.8%3.0%+5.8%
5Y0.1%2.1%-2.0%
10Y10.3%2.0%+8.3%

1.2. Operating Efficiency of LUPIN LTD..

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Lupin is operating .

  • Measures how much profit Lupin makes for each ₹1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Lupin to the Pharmaceuticals industry mean.
  • An Operating Margin of 0.0% means the company generated ₹0.00  for each ₹1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of LUPIN LTD.:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y6.7%-6.7%
5Y6.7%10Y14.3%-7.6%
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
MRQ--5.6%+5.6%
TTM-0.5%-0.5%
YOY-6.2%-6.2%
5Y6.7%5.1%+1.6%
10Y14.3%5.2%+9.1%
1.2.2. Operating Ratio

Measures how efficient Lupin is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Pharmaceuticals industry mean).
  • An Operation Ratio of 1.38 means that the operating costs are ₹1.38 for each ₹1 in net sales.

Let's take a look of the Operating Ratio trends of LUPIN LTD.:

  • The MRQ is 1.383. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.383. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.383TTM1.3830.000
TTM1.383YOY1.263+0.120
TTM1.3835Y1.301+0.081
5Y1.30110Y1.214+0.088
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
MRQ1.3831.342+0.041
TTM1.3831.276+0.107
YOY1.2631.169+0.094
5Y1.3011.149+0.152
10Y1.2141.178+0.036

1.3. Liquidity of LUPIN LTD..

1.3. Liquidity
1.3.1. Current Ratio

Measures if Lupin is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Pharmaceuticals industry mean).
  • A Current Ratio of 1.51 means the company has ₹1.51 in assets for each ₹1 in short-term debts.

Let's take a look of the Current Ratio trends of LUPIN LTD.:

  • The MRQ is 1.505. The company is able to pay all its short-term debts. +1
  • The TTM is 1.505. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ1.505TTM1.5050.000
TTM1.505YOY1.658-0.153
TTM1.5055Y1.898-0.393
5Y1.89810Y1.980-0.082
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
MRQ1.5052.205-0.700
TTM1.5052.010-0.505
YOY1.6582.125-0.467
5Y1.8981.812+0.086
10Y1.9801.786+0.194
1.3.2. Quick Ratio

Measures if Lupin is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Lupin to the Pharmaceuticals industry mean.
  • A Quick Ratio of 0.90 means the company can pay off ₹0.90 for each ₹1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of LUPIN LTD.:

  • The MRQ is 0.899. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.899. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.899TTM0.8990.000
TTM0.899YOY1.420-0.521
TTM0.8995Y1.407-0.507
5Y1.40710Y1.328+0.078
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
MRQ0.8991.118-0.219
TTM0.8991.152-0.253
YOY1.4201.091+0.329
5Y1.4071.007+0.400
10Y1.3280.869+0.459

1.4. Solvency of LUPIN LTD..

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Lupin assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Lupin to Pharmaceuticals industry mean.
  • A Debt to Asset Ratio of 0.44 means that Lupin assets are financed with 44.3% credit (debt) and the remaining percentage (100% - 44.3%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of LUPIN LTD.:

  • The MRQ is 0.443. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.443. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.443TTM0.4430.000
TTM0.443YOY0.415+0.028
TTM0.4435Y0.470-0.027
5Y0.47010Y0.443+0.027
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4430.381+0.062
TTM0.4430.379+0.064
YOY0.4150.417-0.002
5Y0.4700.398+0.072
10Y0.4430.399+0.044
1.4.2. Debt to Equity Ratio

Measures if Lupin is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Lupin to the Pharmaceuticals industry mean.
  • A Debt to Equity ratio of 79.6% means that company has ₹0.80 debt for each ₹1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of LUPIN LTD.:

  • The MRQ is 0.796. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.796. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.796TTM0.7960.000
TTM0.796YOY0.711+0.085
TTM0.7965Y0.894-0.099
5Y0.89410Y0.823+0.071
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
MRQ0.7960.586+0.210
TTM0.7960.598+0.198
YOY0.7110.598+0.113
5Y0.8940.671+0.223
10Y0.8230.664+0.159

2. Market Valuation of LUPIN LTD.

2. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every ₹1 in earnings Lupin generates.

  • Above 15 is considered overpriced but always compare Lupin to the Pharmaceuticals industry mean.
  • A PE ratio of -22.19 means the investor is paying ₹-22.19 for every ₹1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of LUPIN LTD.:

  • The EOD is -22.075. Company is losing money. -2
  • The MRQ is -22.189. Company is losing money. -2
  • The TTM is -22.189. Company is losing money. -2
Trends
Current periodCompared to+/- 
EOD-22.075MRQ-22.189+0.115
MRQ-22.189TTM-22.1890.000
TTM-22.189YOY38.074-60.264
TTM-22.1895Y20.947-43.136
5Y20.94710Y24.552-3.605
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
EOD-22.07540.785-62.860
MRQ-22.18951.661-73.850
TTM-22.18951.419-73.608
YOY38.07464.495-26.421
5Y20.94756.903-35.956
10Y24.55261.712-37.160
2.2. Price Earnings to Growth Ratio

Measures the predicted future growth of Lupin.

  • Lower is better.
  • A PEG ratio of 1 means the market price of the stock and the expected future earnings are on par.

Let's take a look of the Price Earnings to Growth Ratio trends of LUPIN LTD.:

  • The MRQ is 17.697. Seems overpriced? -1
  • The TTM is 17.697. Seems overpriced? -1
Trends
Current periodCompared to+/- 
MRQ17.697TTM17.6970.000
TTM17.697YOY5.847+11.849
TTM17.6975Y324.379-306.683
5Y324.37910Y213.125+111.254
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
MRQ17.6970.015+17.682
TTM17.6970.036+17.661
YOY5.8470.327+5.520
5Y324.3790.144+324.235
10Y213.1250.144+212.981

2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Lupin is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Pharmaceuticals industry mean).
  • A PB ratio of 2.79 means the investor is paying ₹2.79 for each ₹1 in book value.

Let's take a look of the Price to Book Ratio trends of LUPIN LTD.:

  • The EOD is 2.775. Good. +1
  • The MRQ is 2.790. Good. +1
  • The TTM is 2.790. Good. +1
Trends
Current periodCompared to+/- 
EOD2.775MRQ2.790-0.014
MRQ2.790TTM2.7900.000
TTM2.790YOY3.356-0.566
TTM2.7905Y2.635+0.155
5Y2.63510Y4.480-1.845
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
EOD2.7752.248+0.527
MRQ2.7902.690+0.100
TTM2.7903.050-0.260
YOY3.3563.185+0.171
5Y2.6352.899-0.264
10Y4.4802.711+1.769
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of LUPIN LTD. compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---36.835-36.8350%27.646-233%-6.078-84%29.713-224%
Book Value Growth--0.8800.8800%1.101-20%0.982-10%1.081-19%
Book Value Per Share--267.413267.4130%304.248-12%290.204-8%260.651+3%
Book Value Per Share Growth--0.8790.8790%1.100-20%0.982-10%1.081-19%
Current Ratio--1.5051.5050%1.658-9%1.898-21%1.980-24%
Debt To Asset Ratio--0.4430.4430%0.415+7%0.470-6%0.443+0%
Debt To Equity Ratio--0.7960.7960%0.711+12%0.894-11%0.823-3%
Dividend Per Share--6.4936.4930%6.002+8%5.984+9%6.096+7%
Dividend Per Share Growth--1.0821.0820%1.201-10%0.991+9%1.110-3%
Eps---33.622-33.6220%26.815-225%1.235-2822%22.891-247%
Eps Growth---1.254-1.2540%6.511-119%1.465-186%1.338-194%
Free Cash Flow Per Share---11.833-11.8330%25.219-147%10.065-218%2.656-545%
Free Cash Flow Per Share Growth---0.469-0.4690%1.436-133%1.142-141%0.749-163%
Free Cash Flow To Equity Per Share---46.429-46.4290%-16.336-65%-12.396-73%2.964-1666%
Free Cash Flow To Equity Per Share Growth---0.842-0.8420%-5.804+589%-0.858+2%1.403-160%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--86.040--------
Intrinsic Value_10Y_min--67.041--------
Intrinsic Value_1Y_max---7.440--------
Intrinsic Value_1Y_min---7.229--------
Intrinsic Value_3Y_max---10.112--------
Intrinsic Value_3Y_min---9.769--------
Intrinsic Value_5Y_max--1.972--------
Intrinsic Value_5Y_min--0.808--------
Net Profit Margin---0.093-0.0930%0.080-216%0.005-1836%0.076-223%
Operating Margin----0%-0%0.067-100%0.143-100%
Operating Ratio--1.3831.3830%1.263+9%1.301+6%1.214+14%
Pb Ratio2.775-1%2.7902.7900%3.356-17%2.635+6%4.480-38%
Pe Ratio-22.075+1%-22.189-22.1890%38.074-158%20.947-206%24.552-190%
Peg Ratio--17.69717.6970%5.847+203%324.379-95%213.125-92%
Price Per Share742.200-1%746.050746.0500%1020.950-27%766.440-3%1077.800-31%
Price To Total Gains Ratio-24.461+1%-24.588-24.5880%30.341-181%28.846-185%27.226-190%
Profit Growth---1.256-1.2560%6.516-119%1.466-186%1.339-194%
Quick Ratio--0.8990.8990%1.420-37%1.407-36%1.328-32%
Return On Assets---0.070-0.0700%0.052-236%0.000-17868%0.062-212%
Return On Equity---0.126-0.1260%0.088-243%0.001-17762%0.103-222%
Revenue Growth--1.0821.0820%0.986+10%0.990+9%1.053+3%
Total Gains Per Share---30.342-30.3420%33.649-190%-0.094-100%35.808-185%
Total Gains Per Share Growth---0.902-0.9020%3.558-125%0.247-465%0.477-289%
Usd Book Value--1494852210.0001494852210.0000%1697786220.000-12%1618985040.000-8%1453723470.000+3%
Usd Book Value Change Per Share---0.453-0.4530%0.340-233%-0.075-84%0.365-224%
Usd Book Value Per Share--3.2893.2890%3.742-12%3.570-8%3.206+3%
Usd Dividend Per Share--0.0800.0800%0.074+8%0.074+9%0.075+7%
Usd Eps---0.414-0.4140%0.330-225%0.015-2822%0.282-247%
Usd Free Cash Flow---66145710.000-66145710.0000%140729220.000-147%56099562.000-218%31166423.333-312%
Usd Free Cash Flow Per Share---0.146-0.1460%0.310-147%0.124-218%0.033-545%
Usd Free Cash Flow To Equity Per Share---0.571-0.5710%-0.201-65%-0.152-73%0.036-1666%
Usd Price Per Share9.129-1%9.1769.1760%12.558-27%9.427-3%13.257-31%
Usd Profit---187948920.000-187948920.0000%149633190.000-226%6811986.000-2859%127574506.667-247%
Usd Revenue--2017874040.0002017874040.0000%1865044080.000+8%1904332986.000+6%1820650920.000+11%
Usd Total Gains Per Share---0.373-0.3730%0.414-190%-0.001-100%0.440-185%
 EOD+3 -2MRQTTM+0 -0YOY+8 -335Y+11 -3110Y+12 -30

3.2. Fundamental Score

Let's check the fundamental score of LUPIN LTD. based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-22.075
Price to Book Ratio (EOD)Between0-12.775
Net Profit Margin (MRQ)Greater than0-0.093
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.899
Current Ratio (MRQ)Greater than11.505
Debt to Asset Ratio (MRQ)Less than10.443
Debt to Equity Ratio (MRQ)Less than10.796
Return on Equity (MRQ)Greater than0.15-0.126
Return on Assets (MRQ)Greater than0.05-0.070
Total3/10 (30.0%)

3.3. Technical Score

Let's check the technical score of LUPIN LTD. based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose732.300
Total0/1 (0.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2018-03-312019-03-312020-03-312021-03-312022-03-31
Income before Tax  5,468,1008,621,50014,089,600-6,517,3007,572,3009,192,20016,764,500-30,486,600-13,722,100
Operating Income  5,972,9007,836,90013,809,800-7,219,0006,590,80010,317,40016,908,200-30,848,100-13,939,900



Latest Balance Sheet

Balance Sheet of 2022-03-31. Currency in INR. All numbers in thousands.

Summary
Total Assets218,212,200
Total Liabilities96,679,500
Total Stockholder Equity121,532,700
 As reported
Total Liabilities 96,679,500
Total Stockholder Equity+ 121,532,700
Total Assets = 218,212,200

Assets

Total Assets218,212,200
Total Current Assets124,576,800
Long-term Assets124,576,800
Total Current Assets
Cash And Cash Equivalents 6,441,800
Short-term Investments 12,681,400
Net Receivables 42,619,400
Inventory 48,272,500
Other Current Assets 354,700
Total Current Assets  (as reported)124,576,800
Total Current Assets  (calculated)110,369,800
+/- 14,207,000
Long-term Assets
Property Plant Equipment 53,973,000
Goodwill 21,241,000
Intangible Assets 10,065,000
Other Assets 1,806,600
Long-term Assets  (as reported)93,635,400
Long-term Assets  (calculated)87,085,600
+/- 6,549,800

Liabilities & Shareholders' Equity

Total Current Liabilities82,764,400
Long-term Liabilities13,228,000
Total Stockholder Equity121,532,700
Total Current Liabilities
Short-term Debt 37,023,000
Short Long Term Debt 37,023,000
Accounts payable 22,829,100
Other Current Liabilities 2,880,400
Total Current Liabilities  (as reported)82,764,400
Total Current Liabilities  (calculated)99,755,500
+/- 16,991,100
Long-term Liabilities
Long term Debt Total 3,638,200
Long term Debt 1,418,600
Capital Lease Obligations 3,142,200
Long-term Liabilities Other 1,342,400
Long-term Liabilities  (as reported)13,228,000
Long-term Liabilities  (calculated)9,541,400
+/- 3,686,600
Total Stockholder Equity
Retained Earnings 110,726,900
Capital Surplus 10,620,400
Total Stockholder Equity (as reported)121,532,700
Total Stockholder Equity (calculated)121,347,300
+/- 185,400
Other
Capital Stock909,000
Cash and Short Term Investments 19,123,200
Common Stock Shares Outstanding 454,475
Liabilities and Stockholders Equity 218,212,200
Net Debt 27,542,400
Net Invested Capital 159,974,300
Net Working Capital 41,812,400



Balance Sheet

Currency in INR. All numbers in thousands.

 Trend2022-03-312021-03-312020-03-312019-03-312018-03-312017-03-312016-03-312015-03-312014-03-31
> Total Assets 
102,060,300
131,377,400
226,248,600
266,072,800
263,053,800
279,493,700
249,838,500
236,104,400
218,212,200
218,212,200236,104,400249,838,500279,493,700263,053,800266,072,800226,248,600131,377,400102,060,300
   > Total Current Assets 
61,004,500
78,323,500
98,874,000
119,529,300
122,095,400
138,535,800
154,132,100
139,863,700
124,576,800
124,576,800139,863,700154,132,100138,535,800122,095,400119,529,30098,874,00078,323,50061,004,500
       Cash And Cash Equivalents 
7,975,000
4,813,500
290,900
163,400
139,200
9,800,400
24,463,300
7,197,400
6,441,800
6,441,8007,197,40024,463,3009,800,400139,200163,400290,9004,813,5007,975,000
       Short-term Investments 
1,764,100
16,558,900
127,900
21,263,900
3,007,900
21,505,400
24,426,200
33,916,800
12,681,400
12,681,40033,916,80024,426,20021,505,4003,007,90021,263,900127,90016,558,9001,764,100
       Net Receivables 
26,851,300
28,236,400
45,487,600
46,942,200
56,559,300
58,445,000
58,340,800
44,743,200
42,619,400
42,619,40044,743,20058,340,80058,445,00056,559,30046,942,20045,487,60028,236,40026,851,300
       Inventory 
21,294,500
25,035,600
34,206,900
36,422,800
36,624,900
38,367,700
34,568,700
42,787,100
48,272,500
48,272,50042,787,10034,568,70038,367,70036,624,90036,422,80034,206,90025,035,60021,294,500
       Other Current Assets 
2,854,200
3,207,600
4,042,100
8,080,900
11,896,000
10,417,300
12,333,100
404,000
354,700
354,700404,00012,333,10010,417,30011,896,0008,080,9004,042,1003,207,6002,854,200
   > Long-term Assets 
0
0
0
146,531,100
140,958,400
140,957,900
95,706,400
96,240,700
93,635,400
93,635,40096,240,70095,706,400140,957,900140,958,400146,531,100000
       Property Plant Equipment 
28,880,900
31,468,300
43,303,700
53,512,700
58,637,300
59,301,200
51,237,100
52,344,400
53,973,000
53,973,00052,344,40051,237,10059,301,20058,637,30053,512,70043,303,70031,468,30028,880,900
       Goodwill 
6,578,700
16,481,100
22,654,400
23,100,100
24,484,900
23,803,200
18,514,800
19,624,200
21,241,000
21,241,00019,624,20018,514,80023,803,20024,484,90023,100,10022,654,40016,481,1006,578,700
       Long Term Investments 
20,600
25,100
143,300
220,000
305,800
2,275,500
0
0
0
0002,275,500305,800220,000143,30025,10020,600
       Intangible Assets 
1,137,600
1,492,200
48,235,500
55,047,100
46,479,700
44,159,800
19,025,400
17,501,600
10,065,000
10,065,00017,501,60019,025,40044,159,80046,479,70055,047,10048,235,5001,492,2001,137,600
       Long-term Assets Other 
0
0
0
146,531,100
1,588,400
140,957,900
0
792,900
1,375,600
1,375,600792,9000140,957,9001,588,400146,531,100000
> Total Liabilities 
32,075,200
42,395,800
114,614,900
131,097,100
127,283,200
142,071,400
124,471,500
98,073,000
96,679,500
96,679,50098,073,000124,471,500142,071,400127,283,200131,097,100114,614,90042,395,80032,075,200
   > Total Current Liabilities 
26,295,500
37,292,300
50,611,700
61,205,900
50,955,500
61,298,700
92,252,000
84,360,900
82,764,400
82,764,40084,360,90092,252,00061,298,70050,955,50061,205,90050,611,70037,292,30026,295,500
       Short-term Debt 
6,537,400
651,400
17,454,100
23,043,300
4,517,600
15,802,100
24,927,500
30,494,400
37,023,000
37,023,00030,494,40024,927,50015,802,1004,517,60023,043,30017,454,100651,4006,537,400
       Short Long Term Debt 
6,537,400
651,400
581,500
23,043,300
7,182,100
18,543,500
45,120,400
30,494,400
37,023,000
37,023,00030,494,40045,120,40018,543,5007,182,10023,043,300581,500651,4006,537,400
       Accounts payable 
15,941,300
19,560,600
19,888,200
25,889,000
25,754,000
24,981,800
24,123,000
20,144,400
22,829,100
22,829,10020,144,40024,123,00024,981,80025,754,00025,889,00019,888,20019,560,60015,941,300
       Other Current Liabilities 
4,629,100
12,288,500
7,177,000
7,039,700
12,386,300
12,894,100
16,757,100
1,836,900
2,880,400
2,880,4001,836,90016,757,10012,894,10012,386,3007,039,7007,177,00012,288,5004,629,100
   > Long-term Liabilities 
0
0
0
69,546,000
75,926,900
80,304,100
31,829,600
13,162,400
13,228,000
13,228,00013,162,40031,829,60080,304,10075,926,90069,546,000000
       Long term Debt Total 
0
0
53,739,000
56,477,800
64,245,000
66,417,200
20,158,700
2,748,100
3,638,200
3,638,2002,748,10020,158,70066,417,20064,245,00056,477,80053,739,00000
       Capital Lease Obligations 
0
0
0
1,000
2,400
1,300
3,198,000
3,461,000
3,142,200
3,142,2003,461,0003,198,0001,3002,4001,000000
       Long-term Liabilities Other 
0
0
0
0
4,651,600
0
128,500
1,436,900
1,342,400
1,342,4001,436,900128,50004,651,6000000
> Total Stockholder Equity
69,315,700
88,740,600
111,633,700
134,975,700
135,770,600
137,422,300
125,367,000
138,031,400
121,532,700
121,532,700138,031,400125,367,000137,422,300135,770,600134,975,700111,633,70088,740,60069,315,700
   Common Stock
896,800
899,000
901,200
903,200
904,200
905,000
906,000
907,400
909,000
909,000907,400906,000905,000904,200903,200901,200899,000896,800
   Retained Earnings 
59,916,400
79,658,900
102,821,400
123,628,300
122,102,900
125,511,100
119,063,600
129,368,600
110,726,900
110,726,900129,368,600119,063,600125,511,100122,102,900123,628,300102,821,40079,658,90059,916,400
   Capital Surplus 
0
0
6,780,900
7,551,800
8,129,400
8,644,200
9,176,200
9,887,100
10,620,400
10,620,4009,887,1009,176,2008,644,2008,129,4007,551,8006,780,90000
   Treasury Stock000000000
   Other Stockholders Equity 
2,869,200
2,138,600
35,800
2,892,400
4,634,100
2,362,000
-3,778,000
-3,367,000
-2,340,900
-2,340,900-3,367,000-3,778,0002,362,0004,634,1002,892,40035,8002,138,6002,869,200



Balance Sheet

Currency in INR. All numbers in thousands.




Cash Flow

Currency in INR. All numbers in thousands.




Income Statement

Currency in INR. All numbers in thousands.


Latest Income Statement (annual, 2022-03-31)

Gross Profit (+$)
totalRevenue164,054,800
Cost of Revenue-70,421,500
Gross Profit93,633,30093,633,300
 
Operating Income (+$)
Gross Profit93,633,300
Operating Expense-156,421,900
Operating Income-13,939,900-62,788,600
 
Operating Expense (+$)
Research Development-
Selling General Administrative70,693,900
Selling And Marketing Expenses-
Operating Expense156,421,90070,693,900
 
Net Interest Income (+$)
Interest Income329,800
Interest Expense-1,072,600
Net Interest Income-467,700-742,800
 
Pretax Income (+$)
Operating Income-13,939,900
Net Interest Income-467,700
Other Non-Operating Income Expenses-
Income Before Tax (EBT)-13,722,100-13,939,900
EBIT - interestExpense = -1,072,600
-15,280,400
-14,207,800
Interest Expense1,072,600
Earnings Before Interest and Taxes (ebit)--12,649,500
Earnings Before Interest and Taxes (ebitda)3,937,600
 
After tax Income (+$)
Income Before Tax-13,722,100
Tax Provision-1,371,500
Net Income From Continuing Ops-15,093,600-15,093,600
Net Income-15,280,400
Net Income Applicable To Common Shares-15,280,400
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net-467,700
 

Comments

Join the conversation.

Leave a comment

Stay informed with my latest content.

Subscribe to my newsletter and receive an email as soon as I add content to PenkeTrading.com.


By clicking Register, you agree to the General Terms and Conditions.
Penke's Market Notifications
NGU24-NYM.COMM
2 hours ago

I found you a Oversold RSI (Relative Strength Index) on the daily chart of NGU24-NYM.COMM.

NGU24-NYM.COMM Daily Candlestick Chart
NGM24-NYM.COMM
2 hours ago

I found you a Oversold RSI (Relative Strength Index) on the daily chart of NGM24-NYM.COMM.

NGM24-NYM.COMM Daily Candlestick Chart
NGQ24-NYM.COMM
2 hours ago

I found you a Oversold RSI (Relative Strength Index) on the daily chart of NGQ24-NYM.COMM.

NGQ24-NYM.COMM Daily Candlestick Chart
ISKJ.MCX
2 hours ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of ISKJ.MCX.

ISKJ.MCX Daily Candlestick Chart
CHKZ.MCX
2 hours ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of CHKZ.MCX.

CHKZ.MCX Daily Candlestick Chart
VSYD.MCX
2 hours ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of VSYD.MCX.

VSYD.MCX Daily Candlestick Chart
VRSB.MCX
2 hours ago

I found you a Golden Cross on the daily chart of VRSB.MCX.

VRSB.MCX Daily Candlestick Chart
TBRU.MCX
2 hours ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of TBRU.MCX.

TBRU.MCX Daily Candlestick Chart
SNGSP.MCX
2 hours ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of SNGSP.MCX.

SNGSP.MCX Daily Candlestick Chart
RBCM.MCX
2 hours ago

I found you a Golden Cross on the daily chart of RBCM.MCX.

RBCM.MCX Daily Candlestick Chart
OKEY.MCX
2 hours ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of OKEY.MCX.

OKEY.MCX Daily Candlestick Chart
MTLR.MCX
2 hours ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of MTLR.MCX.

MTLR.MCX Daily Candlestick Chart
MRKZ.MCX
2 hours ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of MRKZ.MCX.

MRKZ.MCX Daily Candlestick Chart
KRKN.MCX
2 hours ago

I found you a STOCH Bearish Reversal Divergence on the daily chart of KRKN.MCX.

KRKN.MCX Daily Candlestick Chart
JNOS.MCX
2 hours ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of JNOS.MCX.

JNOS.MCX Daily Candlestick Chart
BLNG.MCX
2 hours ago

I found you a Golden Cross on the daily chart of BLNG.MCX.

BLNG.MCX Daily Candlestick Chart
ASSB.MCX
2 hours ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of ASSB.MCX.

ASSB.MCX Daily Candlestick Chart
CSYZ.MU
2 hours ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of CSYZ.MU.

CSYZ.MU Daily Candlestick Chart
MOH.MU
2 hours ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of MOH.MU.

MOH.MU Daily Candlestick Chart
TBK.V
2 hours ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of TBK.V.

TBK.V Daily Candlestick Chart
UMDK.F
2 hours ago

I found you a STOCH Bullish Hidden Divergence on the daily chart of UMDK.F.

UMDK.F Daily Candlestick Chart
RY4C.BE
2 hours ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of RY4C.BE.

RY4C.BE Daily Candlestick Chart
PLY.BE
2 hours ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of PLY.BE.

PLY.BE Daily Candlestick Chart
PDL.LSE
2 hours ago

I found you a Oversold RSI (Relative Strength Index) on the daily chart of PDL.LSE.

PDL.LSE Daily Candlestick Chart
27F0.MU
3 hours ago

I found you a STOCH Bearish Reversal Divergence on the daily chart of 27F0.MU.

27F0.MU Daily Candlestick Chart